



NZX Announcement

22 May 2020

Truscreen Limited closes public pool offer fully subscribed

Truscreen is pleased to announce that its recently announced offer to raise \$500,000 through a Public Pool has been closed today, fully subscribed.

Truscreen Chairman Tony Ho said *“Truscreen is again delighted with the positive support received from TRU shareholders and members of the public to the recent capital raising initiative. The new capital raised will enable the Company to implement its business strategy”*.

TRU expects that the new shares to be issued pursuant to the Public Pool will be allotted, and holder statements sent out to shareholders on or about Friday 29 May.

Auckland based capital markets advisory firm CM Partners advised TRU on the capital raising initiative.

- ENDS -

For more information, visit www.truscreen.com or contact:

TruScreen

Victoria Potarina

Chief Executive Officer

victoriapotarina@truscreen.com

Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>